Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 30Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 7Neoplasms 6Colorectal Neoplasms 6Adenocarcinoma 6Pancreatic Neoplasms 3Ovarian Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Melanoma 2HER2-positive Gastric Cancer 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Solid Cancer 1

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × HER2-Positive Primary Breast Cancer × trastuzumab deruxtecan × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡